Lundbeck, Otsuka collborate on Alzheimer's

Share this article:

Lundbeck and Otsuka are working together on a vaccine to combat Alzheimer's disease. This would be the duo's third Alzheimer's collaboration, and the agreement tethers the companies through Phase I.

This effort is an anti-beta amyloid vaccine that the companies expect would be used in the elderly. The companies said in a statement that the idea behind the treatment is that it could preserve cognitive function by preventing amyloid-beta deposits from accumulating.

The companies will decide next steps when Phase I ends. They expect the study to start next year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.